Thromboelastography: Coagulation Beyond INR and aPTT
Dr. Dhanesh Sukumaran, Critical Care physician in Saveetha Medical College And Hospital, shared a very insightful post on Thromboelastography on LinkedIn:
”Understanding Coagulation Beyond INR and aPTT – The Power of TEG
In the ICU and OR, we often face complex coagulopathies—massive transfusions, sepsis-induced DIC, liver failure, trauma. Traditional labs like INR, aPTT, and platelet count tell only part of the story.
Enter Thromboelastography (TEG) – a dynamic, real-time assessment of the entire clotting cascade, from clot formation to lysis.
What makes TEG valuable?
- Rapid bedside results
- Guides goal-directed transfusion (PRBC, FFP, platelets, cryo, antifibrinolytics)
- Reduces unnecessary blood product use
- Especially useful in trauma, cardiac surgery, liver transplantation, and sepsis-related coagulopathy
Key parameters:
• R-time: Time to clot initiation (think clotting factors)
• K-time and Alpha angle: Speed of clot formation (fibrinogen function)
• MA (Maximum Amplitude): Strength of the clot (platelet function)
• LY30: Clot stability and fibrinolysis
TEG doesn’t replace conventional tests but complements them—giving us the “big picture” in real time.
If you’re not using TEG in your critical care or perioperative practice yet, it’s time to explore its impact.”
Find more comprehensive insights on coagulation in Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology